Vestal Point Capital LP Invests $23.39 Million in Nyxoah S.A. (NASDAQ:NYXH)

Vestal Point Capital LP bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,924,216 shares of the company’s stock, valued at approximately $23,394,000. Nyxoah comprises approximately 1.4% of Vestal Point Capital LP’s holdings, making the stock its 28th biggest holding. Vestal Point Capital LP owned about 8.59% of Nyxoah as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC raised its stake in Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after purchasing an additional 2,774 shares in the last quarter. Walleye Capital LLC raised its stake in Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock worth $119,000 after purchasing an additional 2,862 shares in the last quarter. Kovack Advisors Inc. raised its stake in Nyxoah by 100.0% in the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after purchasing an additional 10,000 shares in the last quarter. LPL Financial LLC acquired a new stake in Nyxoah in the 4th quarter worth about $102,000. Finally, Ameriprise Financial Inc. acquired a new stake in Nyxoah in the 4th quarter worth about $135,000.

Nyxoah Price Performance

NYXH stock opened at $6.29 on Monday. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. Nyxoah S.A. has a 12 month low of $5.55 and a 12 month high of $11.87. The firm has a market cap of $214.24 million, a P/E ratio of -3.36 and a beta of 1.56. The company’s 50-day moving average price is $7.21 and its two-hundred day moving average price is $8.59.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Wednesday, May 14th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. The firm had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.64 million. On average, analysts anticipate that Nyxoah S.A. will post -1.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Nyxoah in a research note on Tuesday, April 8th. Stifel Nicolaus dropped their price objective on shares of Nyxoah from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, April 21st.

Nyxoah Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.